The Press-Dispatch
Issue link: http://www.ifoldsflip.com/i/1164723
The Press-Dispatch Local Wednesday, September 11, 2019 A- 7 The Press-Dispatch 812-354-8500 | www.pressdispatch.net *By enrolling in the Birthday Club, you agree to have your name, town and birth- day, or the person's name and town and birthday of whom you are enrolling, printed in e Press-Dispatch on the week in which the birthday occurs. Joining is easy! Visit pressdispatch.net/birthday or send your full name, address, city, state, zip code, phone number and birthdate to birthdayclub@pressdispatch.net.* Each week, a list of birthdays will be published in the paper! You could win a FREE PRIZE from area businesses and a three-month subscription to e Press-Dispatch. MUST RE-ENROLL EVERY YEAR! Join the One WINNER is drawn at the end of each month German American Bancorp, Inc. reports earnings German American Ban- corp, Inc. (NASDAQ: GABC) reported record quarterly earnings of $15.3 million, or $ 0.61 per share, for the quarter ending on June 30, 2019. This level of quarterly earnings perfor- mance was an increase of 27 percent, on a per share ba- sis, compared with the sec- ond quarter 2018 net income of $11.1 million, or $ 0.48 per share. The current quarter earnings also compared fa- vorably with the first quar- ter 2019 net income of $15.1 million, or $ 0.60 per share. Fox Found. funding non-invasive detection process of Parkinson's disease By Chris Adam Purdue News Service cladam@prf.org The Michael J. Fox Foun- dation (MJFF) has provid- ed funding to a Purdue Uni- versity-affiliated company working to help make early detection of Parkinson's and other diseases easier and less agonizing for patients. The Michael J. Fox Foun- dation is one of the world's largest organizations fo- cused on the next genera- tion of Parkinson's disease treatments. The foundation is sup- porting Tymora Analytical Operations' efforts to study Parkinson's using the start- up's EVtrap approach, which looks for certain biomarkers in a patient's fluid samples. No specific test exists to diagnose Parkinson's, and current approaches are im- perfect. The disease is typ- ically diagnosed at a late stage, when the symptoms are apparent and treatment has limited effectiveness. "This award will sup- port our analysis work to find new urine biomarkers, which can lead to early Par- kinson's disease diagnoses and treatments," said Anton Iliuk, Tymora's chief tech- nology officer. Tymora's EVtrap ap- proach involves analyzing a urine sample to look for exosome proteins and phos- phoproteins that are Parkin- son's-signaling molecules in the body. "Because there is no spe- cific test for Parkinson's dis- ease, doctors often review medical histories and per- form neurological and physi- cal examinations, which can often be inconclusive," Ili- uk said. "Our approach us- es a simple urine test, of- ten already performed dur- ing regular exams, to look for biomarkers. Diagnosing Parkinson's at an early stage with our method would give doctors a greater opportuni- ty to successfully treat the condition." The Tymora scientists will analyze more than 100 samples provided by MJFF to look for specific proteins found in Parkinson's disease that contain enzymatically- attached phosphate groups. The chief scientific officer for Tymora, W. Andy Tao, is a professor of biochemistry in Purdue's College of Ag- riculture, and a member of the Purdue University Cen- ter for Cancer Research. Tao developed much of Tymora's technology at Purdue Uni- versity and licensed the in- tellectual property through the Purdue Research Foun- dation Office of Technology Commercialization. He also is the 2017 recipient of the Outstanding Commercial- ization Award for Purdue University faculty. The technology aligns with Purdue's Giant Leaps celebration of the universi- ty's global advancements in health as part of Purdue's 150th anniversary. That is one of the four themes of the yearlong celebration's Ideas Festival, designed to showcase Purdue as an in- tellectual center solving re- al-world issues.